Eosinophilic esophagitis: current knowledge and management options?
DOI: 10.32364/2587-6821-2024-8-3-5
E.B. Belan, E.V. Tibir'kova
Volgograd State Medical University, Volgograd, Russian Federation
Eosinophilic esophagitis is a chronic immune-mediated disease of the esophagus. It is characterized by severe eosinophilic inflammation of the esophageal mucosa and the develop-ment of submucosal fibrosis. Clinically, it is manifested by swallowing disorders. The pathogen-esis is based on genetically determined disorder of immune response and barrier function of the esophageal mucosa. The diagnosis of esophageal eosinophilic infiltration is established by clinical manifestations and morphology, after excluding diseases that cause esophageal eosinophilia. The criterion for diagnosis is intraepithelial eosinophilic infiltration with 15 or more eosinophils per field of view at magnification ×400 (or ≥60 eosinophils per 1 mm2). Secondary tests, such as measuring serum total immunoglobulin E levels, assessing peripheral blood eosinophilia, and skin allergy tests, are of lesser importance. The primary treatment for this condition is proton pump inhibitors. If the effect is insufficient, topical steroids and dietary restrictions may also be prescribed. Treatment effectiveness is evaluated 6–12 weeks after initiation by analyzing symp-toms and performing esophagogastroduodenoscopy with biopsy. Endoscopic dilatation is rec-ommended as a treatment option for patients experiencing severe dysphagia caused by esopha-geal narrowing. Biologic agents may also be considered as a possible treatment option.
Keywords: eosinophilic esophagitis, esophageal dysfunction, intraepithelial eosinophilic infiltration, proton pump inhibitors, topical steroids, diet, endoscopic dilatation, biologic agents.
For citation: Belan E.B., Tibir'kova E.V. Eosinophilic esophagitis: current knowledge and management options? Russian Medical Inquiry. 2024;8(3):150–154 (in Russ.). DOI: 10.32364/2587-6821-2024-8-3-5.
ABOUT THE AUTHORS:
Eleonora B. Belan — Dr. Sc. (Med.), Professor, Head of the Department of Allergy and Immunology, Volgograd State Medical University; 1, Pavshikh Bortsov sq., Volgograd, 400131, Russian Federation; ORCID iD 0000-0003-2674-4289.
Elena V. Tibir'kova — C. Sc. (Med.), associate professor of the Department of Allergy and Immunology, Volgograd State Medical University; 1, Pavshikh Bortsov sq., Volgograd, 400131, Russian Federation; ORCID iD 0000-0003-0972-5238.
Contact information: Eleonora B. Belan, e-mail: belan.eleonora@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 21.02.2024.
Revised 12.03.2024.
Accepted 28.03.2024.
2. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эозинофильного эзофагита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(6):84–98. DOI: 10.22416/1382-4376-2018-28-6-84-98. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis. Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis. Russian Journal of Gastroentorology, Hepatology, Coloproctology. 2018;28(6):84–98 (in Russ.). DOI: 10.22416/1382-4376-2018-28-6-84-98.
3. Arias Á., Pérez-Martínez I., Tenías J.M., Lucendo A.J. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3–15. DOI: 10.1111/apt.13441.
4. Ираклионова Н.С., Туркина С.В., Белан Э.Б. Эозинофильный эзофагит: этиология, патогенез, диагностика, лечение. Лекарственный вестник. 2017;3(67):42–53. Iraklionova N.S., Turkina S.V., Belan E.B. Eosinophilic esophagitis: etiology, pathogenesis, diagnosis, treatment. lekarstvennyj vestnik. 2017;3(67):42–53 (in Russ.).
5. González-Cervera J., Arias Á., Redondo-González O. et al. Association between atopic manifestations and eosinophilic esophagitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;118(5):582–590.e2. DOI: 10.1016/j.anai.2017.02.006.
6. Кайбышева В.О., Михалева Л.М., Никонов Е.Л., Шаповальянц С.Г. Эпидемиология, этиология и патогенез эозинофильного эзофагита. Новейшие данные. Доказательная гастроэнтерология. 2019;8(2):50–72. DOI: 10.17116/dokgastro2019802150. Kaibysheva V.O., Mikhaleva L.M., Nikonov E.L., Shapoval'yants S.G. Epidemiology, etiology and pathogenesis of eosinophilic esophagitis. The latest data. Russian Journal of Evidence-Based Gastroenterology. 2019;8(2):50–72 (in Russ.). DOI: 10.17116/dokgastro2019802150.
7. Prematta T., Kunselman A., Ghaffari G. Comparison of Food and Aeroallergen Sensitivity between Adults and Children with Eosinophilic Esophagitis. J Aller Ther. 2011;S3:001. DOI: 10.4172/2155-6121.S3-001.
8. Papadopoulou A., Dias J.A. Eosinophilic esophagitis: an emerging disease in childhood — review of diagnostic and management strategies. Front Pediatr. 2014;2:129. DOI: 10.3389/fped.2014.00129.
9. Ивашкин В.Т., Баранская Е.К., Трухманов А.С., Кайбышева В.О. Эозинофильный эзофагит: учебное пособие для врачей. М.: АИСПИ РАН; 2013. Ivashkin V.T., Baranskaya E.K., Trukhmanov A.S., Kaibysheva V.O. Eosinophilic esophagitis. A training manual for doctors. M.: AISPI RAN; 2013 (in Russ.).
10. D'Alessandro A., Esposito D., Pesce M. et al. Eosinophilic esophagitis: From pathophysiology to treatment. World J Gastrointest Pathophysiol. 2015;6(4):150–158. DOI: 10.4291/wjgp.v6.i4.150.
11. Hill D.A., Spergel J.M. The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep. 2016;16(2):9. DOI: 10.1007/s11882-015-0592-3.
12. Sorge A., Masclee G.M.C., Bredenoord A.J. Endoscopic Diagnosis and Response Evaluation in Patients with Eosinophilic Esophagitis. Curr Treat Options Gastro. 2023;21:256–271. DOI: 10.1007/s11938-023-00428-y.
13. Dhar A., Haboubi H.N., Attwood S.E. et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022;71(8):1459–1487. DOI: 10.1136/gutjnl-2022-327326.
14. Кайбышева В.О., Кашин С.В., Михалева Л.М. и др. Эозинофильный эзофагит: современный взгляд на проблему и собственные клинические наблюдения. Доказательная гастроэнтерология. 2019;8(1):58–83. DOI: 10.17116/dokgastro2019801158. Kaibysheva V.O., Kashin S.V., Mikhaleva L.M. et al. Eosinophilic esophagitis: current view on the problem and own clinical observations. Russian Journal of Evidence-based Gastroenterology. 2019;8(1):58–83 (in Russ.). DOI: 10.17116/dokgastro2019801158.
15. Захарова И.Н., Османов И.М., Пампура А.Н. и др. Эозинофильный эзофагит: все еще трудно и редко диагностируемое состояние. Клинический случай. Педиатрия. Consilium Medicum. 2021;1:57–62. DOI: 10.26442/26586630.2021.1.200838. Zakharova I.N., Osmanov I.M., Pampura A.N. et al. Eosinophilic esophagitis: still a difficult condition to diagnose. Case report. Pediatrics. Consilium Medicum. 2021;1:57–62 (in Russ.). DOI: 10.26442/26586630.2021.1.200838.
16. Макушина А.А., Сторонова О.А., Трухманов А.С. и др. Эффективность монотерапии топическими глюкокортикостероидами в достижении и поддержании клинической и гистологической ремиссии у подростков и взрослых пациентов с эозинофильным эзофагитом: систематический обзор и мета-анализ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):27–37. DOI: 10.22416/1382-4376-2022-32-4-27-37. Makushina A.A., Storonova O.A., Trukhmanov A.S. et al. Efficacy of Topical Corticosteroid Monotherapy in Inducing and Maintaining Clinical and Histologic Remission in Adolescent and Adult Patients with Eosinophilic Esophagitis: a Systematic Review and Meta-Analysis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):27–37 (in Russ.). DOI: 10.22416/1382-4376-2022-32-4-27-37.
17. Lucendo A.J., Molina-Infante J., Arias Á. et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–358. DOI: 10.1177/2050640616689525.
18. Dellon E.S., Woosley J.T., Arrington A. et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology. 2019;157(1):65–73.e5. DOI: 10.1053/j.gastro.2019.03.014.
19. Straumann A., Lucendo A.J., Miehlke S. et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672–1685.e5. DOI: 10.1053/j.gastro.2020.07.039.
20. Arias A., González-Cervera J., Tenias J.M., Lucendo A.J. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–1648. DOI: 10.1053/j.gastro.2014.02.006.
21. Molina-Infante J., Arias A., Barrio J. et al. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol. 2014;134(5):1093–1099. DOI: 10.1016/j.jaci.2014.07.023.
22. Wolf W.A., Jerath M.R., Sperry S.L.W. et al. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12(8):1272–1279. DOI: 10.1016/j.cgh.2013.12.034.
23. Lucendo A.J. Meta-analysis-based guidance for dietary management in eosinophilic esophagitis. Curr Gastroenterol Rep. 2015;17(10):464. DOI: 10.1007/s11894-015-0464-y.
24. Peterson K.A., Byrne K.R., Vinson L.A. et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013;108(5):759–766. DOI: 10.1038/ajg.2012.468.
25. Lucendo A.J., Molina-Infante J. Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it. Curr Opin Gastroenterol. 2018;34(4):226–232. DOI: 10.1097/MOG.0000000000000442.
26. Moawad F.J., Molina-Infante J., Lucendo A.J. et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96–105. DOI: 10.1111/apt.14123.
27. Hirano I., Dellon E.S., Hamilton J.D. et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults with Active Eosinophilic Esophagitis. Gastroenterology. 2020;158(1):111–122.e10. DOI: 10.1053/j.gastro.2019.09.042.
28. Dellon E.S., Rothenberg M.E., Collins M.H. et al. A phase 3, randomized, 3-Part Study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from Part A. Am J Gastroenterol. 2020;115(1):LB3.
29. Straumann A., Hoesli S., Bussmann C. et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013;68(3):375–385. DOI: 10.1111/all.12096.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
